Observational Study
Copyright ©The Author(s) 2023.
World J Clin Cases. Nov 6, 2023; 11(31): 7610-7618
Published online Nov 6, 2023. doi: 10.12998/wjcc.v11.i31.7610
Table 1 Comparison of basic data between the two groups, n (%) (mean ± SD)
Group
Number of cases
Age (yr)
Man
Woman
Weight (kg)
Course of disease (mo)
Vitamin D consumption D (ng/mL)
Spring (n)
Summer (n)
Autumn (n)
Winter (n)
Observation group657.86 ± 1.5635 (53.85)30 (46.15)25.3 ± 3.187.6 ± 2.527.5 ± 5.871581428
Control group658.36 ± 1.2836 (55.38)29 (44.62)26.7 ± 3.896.9 ± 3.226.8 ± 6.2121101123
χ2/1.8930.8950.9680.9870.7981.5622.784
P value/0.5620.2560.5270.3320.1890.6360.546
Table 2 Comparison of efficacy between the two groups, n (%)
Group
Number of cases
Obvious effect
Effective
Ineffective
Total effective efficacy rate
Control group6530 (46.15)29 (44.62)6 (9.23)59 (90.77)
Control group6538 (58.46)25 (38.46)2 (3.08)63 (96.92)a
χ29.562
P value0.001
Table 3 Comparison of clinical cough score between the two groups
Clinical cough scorePre-treatment
tP valuePost-treatment
tP value
Observation group (n = 65)
Control group (n = 65)
Observation group (n = 65)
Control group (n = 65)
Cough score2.06 ± 1.222.26 ± 1.631.0670.2870.56 ± 0.54a0.97 ± 0.473.7850.001
Nighttime coughs3.16 ± 2.013.28 ± 1.061.8920.0921.03 ± 0.25a2.89 ± 0.987.8940.012
Table 4 Comparison of pulmonary function between the two groups
Pulmonary unction indexPre-treatment
tP valuePost-treatment
tP value
Observation group (n = 65)
Control group (n = 65)
Observation group (n = 65)
Control group (n = 65)
MVV (L/min)4.26 ± 0.224.32 ± 0.631.9560.6437.36 ± 1.54a5.97 ± 1.474.2780.003
FEV1 (L)1.16 ± 0.211.28 ± 0.661.5370.2913.43 ± 1.25a1.89 ± 0.982.0890.014
FEV1/FVC (%)64.6 ± 5.3465.4 ± 4.650.9580.45279.8 ± 5.56a73.8 ± 5.062.5630.013
PEF (L/s)2.23 ± 0.562.08 ± 0.581.0710.7493.56 ± 0.78a3.05 ± 0.542.4170.021
Table 5 Comparison of inflammatory response between the two groups before and after treatment (mean ± SD)
Inflammatory response index
Pre-treatment
t
P value
Post-treatment
t
P value
Observation group (n = 65)
Control group (n = 65)
Observation group (n = 65)
Control group (n = 65)
IL-6 (ng/L)25.78 ± 5.1825.32 ± 4.632.1320.09720.36 ± 4.54b21.9 ± 5.471.8910.012
IL-4 (ng/L)24.6 ± 4.3423.4 ± 3.651.2670.25820.8 ± 5.56b22.8 ± 5.061.6730.018
TNF-α (μg/L)1.27 ± 0.321.28 ± 0.631.8790.7840.43 ± 0.25b0.89 ± 0.482.6930.014
Table 6 Comparison of T-lymphocytes count between the two groups before and after treatment (mean ± SD)
GroupCD3+ (%)
tP valueCD4+ (%)
tP valueCD8+ (%)
tP value
Pre-treatment Post-treatment
Post-treatment Post-treatment
Pre-treatment Post-treatment
Post-treatment Post-treatment
Pre-treatment Post-treatment
Post-treatment Post-treatment
Observation group (n = 65)44.6 ± 6.3467.4 ± 4.65-8.250.00829.8 ± 5.5642.8 ± 5.06-9.780.01133.2 ± 5.2125.6 ± 4.8910.60.012
Control group (n = 65)44.7 ± 7.3258.8 ± 5.63-2.670.00428.3 ± 5.2538.9 ± 7.48-8.960.01232.7 ± 6.1828.5 ± 5.129.780.023
t1.7852.1650.8952.4180.7940.947
P value0.5620.0240.7320.0020.0010.003
Table 7 Comparison of immunoglobulin levels between the two groups before and after treatment (mean ± SD)
GroupIgA (g/L)
tP valueIgM (g/L)
tP value
Pre-treatment Post-treatment
Post-treatment Post-treatment
Pre-treatment Post-treatment
Post-treatment Post-treatment
Observation group (n = 65)1.26 ± 0.341.84 ± 0.65-7.230.0129.08 ± 1.5611.8 ± 1.06-6.980.021
Control group (n = 65)1.27 ± 0.321.48 ± 0.63-9.670.0079.03 ± 1.2510.9 ± 1.48-9.560.032
t0.7656.1650.6552.418
P value0.7240.0140.7510.012
Table 8 Comparison of airway anatomical index between the two groups before and after treatment (mean ± SD)
GroupAirway wall thickness(mm2)
tP valueTotal airway wall area(mm2)
tP value
Pre-treatment Post-treatment
Post-treatment Post-treatment
Pre-treatment Post-treatment
Post-treatment Post-treatment
Observation group (n = 65)2.16 ± 0.460.84 ± 0.658.260.0147.08 ± 0.563.28 ± 1.2610.980.011
Control group (n = 65)2.27 ± 0.221.98 ± 0.437.640.0057.03 ± 0.254.39 ± 1.6811.560.006
t1.7628.1350.3984.468
P value0.4250.0160.2160.016